Vaxcyte启动5亿美元公开发行股票和认购证

2026-01-30 05:20

Vaxcyte (PCVX) on Thursday said that it has commenced an underwritten public offering of $500 million of common stock and pre-funded warrants.
The clinical-stage vaccine developer said all securities in the offering will be sold by the company and that it intends to grant underwriters a 30-day option to purchase up to an additional $75 million of common stock, including shares underlying the pre-funded warrants.
The offering is subject to market and other conditions, and there is no assurance on the timing, size or terms of completion, the company said.
PCVX -3.91% after hours to $50.75.
Source: Press Release

More on Vaxcyte